From Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; The University of Texas MD Anderson Cancer Center; UC San Diego Moores Cancer Center; Moffitt Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Roswell Park Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; UCSF Helen Diller Family Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; City of Hope Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and National Comprehensive Cancer Network.
J Natl Compr Canc Netw. 2014 Jun;12(6):853-62. doi: 10.6004/jnccn.2014.0080.
Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)-activating mutations. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.
胃肠道间质瘤（GIST）是胃肠道最常见的软组织肉瘤，主要由 KIT 或血小板衍生生长因子受体α（PDGFRα）激活突变引起。这些 NCCN 指南见解强调了 NCCN 软组织肉瘤指南的重要更新，这些更新专门针对接受伊马替尼和/或舒尼替尼治疗时疾病进展的 GIST 患者的管理。
